- Home
- GNFT vs OABI Comparison
GNFT vs OABI Comparison
Compare GNFT & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- OABI
- Stock Information
- Founded
- GNFT 1999
- OABI 2012
- Country
- GNFT France
- OABI United States
- Employees
- GNFT N/A
- OABI N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- GNFT Health Care
- OABI Health Care
- Exchange
- GNFT Nasdaq
- OABI Nasdaq
- Market Cap
- GNFT 216.7M
- OABI 239.0M
- IPO Year
- GNFT 2019
- OABI N/A
- Fundamental
- Price
- GNFT $4.26
- OABI $1.67
- Analyst Decision
- GNFT Strong Buy
- OABI Strong Buy
- Analyst Count
- GNFT 2
- OABI 3
- Target Price
- GNFT $10.00
- OABI $6.67
- AVG Volume (30 Days)
- GNFT 7.2K
- OABI 504.6K
- Earning Date
- GNFT 09-22-2025
- OABI 11-04-2025
- Dividend Yield
- GNFT N/A
- OABI N/A
- EPS Growth
- GNFT N/A
- OABI N/A
- EPS
- GNFT N/A
- OABI N/A
- Revenue
- GNFT $52,994,715.00
- OABI $23,027,000.00
- Revenue This Year
- GNFT $3.14
- OABI N/A
- Revenue Next Year
- GNFT N/A
- OABI $48.74
- P/E Ratio
- GNFT N/A
- OABI N/A
- Revenue Growth
- GNFT N/A
- OABI 6.05
- 52 Week Low
- GNFT $2.55
- OABI $1.22
- 52 Week High
- GNFT $6.03
- OABI $4.87
- Technical
- Relative Strength Index (RSI)
- GNFT 54.99
- OABI 55.50
- Support Level
- GNFT $4.08
- OABI $1.64
- Resistance Level
- GNFT $4.40
- OABI $1.76
- Average True Range (ATR)
- GNFT 0.16
- OABI 0.10
- MACD
- GNFT 0.02
- OABI 0.01
- Stochastic Oscillator
- GNFT 67.24
- OABI 52.26
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.